Results 41 to 50 of about 22,035 (254)

Molecular Modeling Evaluation of the Binding Effect of Ritonavir, Lopinavir and Darunavir to Severe Acute Respiratory Syndrome Coronavirus 2 Proteases

bioRxiv, 2020
Three anti-HIV drugs, ritonavir, lopinavir and darunavir, might have therapeutic effect on coronavirus disease 2019 (COVID-19). In this study, the structure models of two severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteases, coronavirus
Shen Lin, Runnan Shen, Jingdong He, Xinhao Li, Xushun Guo   +4 more
semanticscholar   +1 more source

Mass spectrometry captures off-target drug binding and provides mechanistic insights into the human metalloprotease ZMPSTE24. [PDF]

, 2016
Off-target binding of hydrophobic drugs can lead to unwanted side effects, either through specific or non-specific binding to unintended membrane protein targets.
Carpenter, Elisabeth P, Gault, Joseph, Marcoux, Julien, Mehmood, Shahid, Michaelis, Susan, Quigley, Andrew, Robinson, Carol V, Young, Stephen G   +7 more
core   +2 more sources

Pharmacokinetics of darunavir and cobicistat in pregnant and postpartum women with HIV

AIDS (London), 2021
Objective: To evaluate darunavir and cobicistat pharmacokinetics during pregnancy compared with postpartum and in infant washout samples after delivery.
J. Momper, Jiajia Wang, A. Stek, D. Shapiro, G. Scott, M. Paul, I. Febo, S. Burchett, E. Smith, N. Chakhtoura, Kayla Denson, K. Rungruengthanakit, K. George, Derek Z Yang, E. Capparelli, M. Mirochnick, B. Best   +16 more
semanticscholar   +1 more source

Comprehensive Study of Antiretroviral Drug Permeability at the Cervicovaginal Mucosa via an In Vitro Model

Pharmaceutics, 2022
Modulation of drug transporter activity at mucosal sites of HIV-1 transmission may be exploited to optimize retention of therapeutic antiretroviral drug concentrations at target submucosal CD4+ T cells.
Constandinos Carserides, Kieron Smith, Marta Zinicola, Abhinav Kumar, Magda Swedrowska, Carlo Scala, Gary Cameron, Zoe Riches, Francesco Iannelli, Gianni Pozzi, Georgina L. Hold, Ben Forbes, Charles Kelly, Karolin Hijazi   +13 more
doaj   +1 more source

Switching to a NRTI-free 2 drug regimen (2DR) –a sub-analysis of the 48 weeks DUALIS study on metabolic and renal changes

HIV Research & Clinical Practice, 2022
Background/Aims: Switching from a three-drug regimen (3DR: boosted darunavir [bDRV] and two nucleoside reverse transcriptase inhibitors [NRTIs]) to a two-drug regimen (2DR: bDRV and dolutegravir [DTG]) demonstrated non-inferiority with regard to viral ...
Malte Monin, Tim Kümmerle, Jochen Schneider, Christiane Cordes, Hans Heiken, Hans-Jürgen Stellbrink, Ivanka Krznaric, Stefan Scholten, Björn Jensen, Heiko Jessen, Wilfried Obst, Petra Spornraft-Ragaller, Pavel Khaykin, Annamaria Balogh, Eva Wolf, Helen Bidner, Christoph D. Spinner, Christoph Boesecke, on behalf of the DUALIS STUDY GROUP   +18 more
doaj   +1 more source

Combinations of isoform-targeted histone deacetylase inhibitors and bryostatin analogues display remarkable potency to activate latent HIV without global T-cell activation [PDF]

, 2017
Current antiretroviral therapy (ART) for HIV/AIDS slows disease progression by reducing viral loads and increasing CD4 counts. Yet ART is not curative due to the persistence of CD4+ T-cell proviral reservoirs that chronically resupply active virus ...
Albert, Brice J, Barnes, Alexander B, Kyei, George B, Marshall, Garland R, Niu, Austin, Ramani, Rashmi, Ratner, Lee, Wender, Paul A, Williams, Robert M   +8 more
core   +2 more sources

HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UK [PDF]

, 2016
BACKGROUND: Darunavir is considered to have a high genetic barrier to resistance. Most darunavir-associated drug resistance mutations (DRMs) have been identified through correlation of baseline genotype with virological response in clinical trials ...
(UKHDRD) and the UK Collaborative HIV Cohort (UK CHIC) Study Ste,, Dunn, DT, El Bouzidi, K, Mackie, N, Mbisa, JL, Phillips, AN, Pillay, D, Pozniak, AL, Sabin, CA, Tostevin, A, UK HIV Drug Resistance Database (UKHDRD) and the UK Collaborativ,, UK HIV Drug Resistance Database,, White, E   +12 more
core   +1 more source

Efficacy and safety of darunavir and etravirine in an antiretroviral multi-experienced youth with vertically HIV-1 infection

European Journal of Medical Research, 2009
Multiclass-drug resistance, often caused by poor treatment compliance, is a challenging problem in all categories of HIV-infected patients. Selective pressure is higher in youth for both biological and behavioral reasons.
Rosso R, Bernardini C, Bruzzone B, Secondo G, Icardi G, Viscoli C, Di Biagio A   +6 more
doaj   +1 more source

Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR [PDF]

, 2019
The main targets for neutralizing anti-hepatitis C virus (HCV) antibodies (HCV-nAbs) are the E1 and E2 envelope glycoproteins. We have studied the characteristics of HCV-nAbs through a retrospective study involving 29 HIV/HCV-coinfected patients who ...
Berenguer, Juan, Carrero, Ana, Crespo, Manuel, González García, Juan, Guardional, Josep M., Gómez, Julián, Jiménez Sousa, María Angeles, Martínez, Isidoro, Resino, Salvador, Santos, Ignacio de los, The GESIDA 3603b Cohort Study Group, Vigón, Lorena, Von Wichmann, Miguel A., Vázquez Morón, Sonia, Yélamos, María Belén   +14 more
core   +4 more sources

Highlights from the 24th conference on retroviruses and opportunistic infections, 13-16 February 2017, Seattle, Washington, USA [PDF]

, 2017
From the 13th to 16th February 2017, researchers from around the world convened for the 24th annual Conference on Retroviruses and Opportunistic Infections (CROI) at the Washington State Convention Center in Seattle, Washington.
Bhagani, Sanjay, Colby, Donn J, Crowell, Trevor A, Gathogo, Esther N, Hill, Andrew, Hsu, Denise, Kinloch, Sabine, Lyall, Hermione, Malatinková, Eva, Polyak, Christina, Psomas, Christina, Trypsteen, Wim, Vandekerckhove, Linos   +12 more
core   +5 more sources